The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy
Head and neck squamous cell carcinoma (HNSCC) encompass a group of complex entities of tumours affecting the aerodigestive upper tract. The main risk factors are strongly related to tobacco and alcohol consumption, but also HPV infection is often associated. Surgery, radiotherapy and/or chemotherapy...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1021609/full |
| _version_ | 1798027628547932160 |
|---|---|
| author | Marcos Paulo S. Damasio Camila Sales Nascimento Lidia M. Andrade Vivian L. de Oliveira Vivian L. de Oliveira Carlos Eduardo Calzavara-Silva |
| author_facet | Marcos Paulo S. Damasio Camila Sales Nascimento Lidia M. Andrade Vivian L. de Oliveira Vivian L. de Oliveira Carlos Eduardo Calzavara-Silva |
| author_sort | Marcos Paulo S. Damasio |
| collection | DOAJ |
| description | Head and neck squamous cell carcinoma (HNSCC) encompass a group of complex entities of tumours affecting the aerodigestive upper tract. The main risk factors are strongly related to tobacco and alcohol consumption, but also HPV infection is often associated. Surgery, radiotherapy and/or chemotherapy are the standard treatments, though the 5-year overall survival is less than 50%. The advances in genomics, molecular medicine, immunology, and nanotechnology have shed a light on tumour biology which helps clinical researchers to obtain more efficacious and less toxic therapies. Head and neck tumours possess different immune escape mechanisms including diminishing the immune response through modulating immune checkpoints, in addition to the recruitment and differentiation of suppressive immune cells. The insights into the HNSCC biology and its strong interaction with the tumour microenvironment highlights the role of immunomodulating agents. Recently, the knowledge of the immunological features of these tumours has paved the way for the discovery of effective biomarkers that allow a better selection of patients with odds of improving overall survival through immunotherapy. Specially biomarkers regarding immune checkpoint inhibitors antibodies, such as anti-PD-1/PD-L1 and anti-CTLA-4 in combination with standard therapy or as monotherapy. New immunotherapies to treat head and neck cancer carcinomas, such as CAR T cells and nanoparticles have been the center of attention and in this review, we discuss the necessity of finding targets for the T cell in the cancer cells to generate CAR T cells, but also the relevance of evaluating specificity and safety of those therapies. |
| first_indexed | 2024-04-11T18:55:38Z |
| format | Article |
| id | doaj.art-c6a30f4a76414103942c85e9ed248748 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T18:55:38Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-c6a30f4a76414103942c85e9ed2487482022-12-22T04:08:13ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-10-011210.3389/fonc.2022.10216091021609The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapyMarcos Paulo S. Damasio0Camila Sales Nascimento1Lidia M. Andrade2Vivian L. de Oliveira3Vivian L. de Oliveira4Carlos Eduardo Calzavara-Silva5Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesGrupo de pesquisa em Imunologia Celular e Molecular, Fundação Oswaldo Cruz, Instituto Rene Rachou, Belo Horizonte, MG, BrazilDepartamento de Genética, Ecologia e Evolução, Departamento de Física, Nanobiomedical Research Group, Universidade Federal de Minas Gerais, Belo Horizonte, MG, BrazilUniversidade Federal do ABC, Centro de Ciências Naturais e Humanas, São Paulo, BrazilLaboratório de Imunologia, LIM19, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, BrazilGrupo de pesquisa em Imunologia Celular e Molecular, Fundação Oswaldo Cruz, Instituto Rene Rachou, Belo Horizonte, MG, BrazilHead and neck squamous cell carcinoma (HNSCC) encompass a group of complex entities of tumours affecting the aerodigestive upper tract. The main risk factors are strongly related to tobacco and alcohol consumption, but also HPV infection is often associated. Surgery, radiotherapy and/or chemotherapy are the standard treatments, though the 5-year overall survival is less than 50%. The advances in genomics, molecular medicine, immunology, and nanotechnology have shed a light on tumour biology which helps clinical researchers to obtain more efficacious and less toxic therapies. Head and neck tumours possess different immune escape mechanisms including diminishing the immune response through modulating immune checkpoints, in addition to the recruitment and differentiation of suppressive immune cells. The insights into the HNSCC biology and its strong interaction with the tumour microenvironment highlights the role of immunomodulating agents. Recently, the knowledge of the immunological features of these tumours has paved the way for the discovery of effective biomarkers that allow a better selection of patients with odds of improving overall survival through immunotherapy. Specially biomarkers regarding immune checkpoint inhibitors antibodies, such as anti-PD-1/PD-L1 and anti-CTLA-4 in combination with standard therapy or as monotherapy. New immunotherapies to treat head and neck cancer carcinomas, such as CAR T cells and nanoparticles have been the center of attention and in this review, we discuss the necessity of finding targets for the T cell in the cancer cells to generate CAR T cells, but also the relevance of evaluating specificity and safety of those therapies.https://www.frontiersin.org/articles/10.3389/fonc.2022.1021609/fullT-cellHNSCCtumor immune evasioncheckpoint inhibitorsimmunotherapynanomedicine |
| spellingShingle | Marcos Paulo S. Damasio Camila Sales Nascimento Lidia M. Andrade Vivian L. de Oliveira Vivian L. de Oliveira Carlos Eduardo Calzavara-Silva The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy Frontiers in Oncology T-cell HNSCC tumor immune evasion checkpoint inhibitors immunotherapy nanomedicine |
| title | The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy |
| title_full | The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy |
| title_fullStr | The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy |
| title_full_unstemmed | The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy |
| title_short | The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy |
| title_sort | role of t cells in head and neck squamous cell carcinoma from immunity to immunotherapy |
| topic | T-cell HNSCC tumor immune evasion checkpoint inhibitors immunotherapy nanomedicine |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1021609/full |
| work_keys_str_mv | AT marcospaulosdamasio theroleoftcellsinheadandnecksquamouscellcarcinomafromimmunitytoimmunotherapy AT camilasalesnascimento theroleoftcellsinheadandnecksquamouscellcarcinomafromimmunitytoimmunotherapy AT lidiamandrade theroleoftcellsinheadandnecksquamouscellcarcinomafromimmunitytoimmunotherapy AT vivianldeoliveira theroleoftcellsinheadandnecksquamouscellcarcinomafromimmunitytoimmunotherapy AT vivianldeoliveira theroleoftcellsinheadandnecksquamouscellcarcinomafromimmunitytoimmunotherapy AT carloseduardocalzavarasilva theroleoftcellsinheadandnecksquamouscellcarcinomafromimmunitytoimmunotherapy AT marcospaulosdamasio roleoftcellsinheadandnecksquamouscellcarcinomafromimmunitytoimmunotherapy AT camilasalesnascimento roleoftcellsinheadandnecksquamouscellcarcinomafromimmunitytoimmunotherapy AT lidiamandrade roleoftcellsinheadandnecksquamouscellcarcinomafromimmunitytoimmunotherapy AT vivianldeoliveira roleoftcellsinheadandnecksquamouscellcarcinomafromimmunitytoimmunotherapy AT vivianldeoliveira roleoftcellsinheadandnecksquamouscellcarcinomafromimmunitytoimmunotherapy AT carloseduardocalzavarasilva roleoftcellsinheadandnecksquamouscellcarcinomafromimmunitytoimmunotherapy |